In the article, “Progess for Stroke Prevention With Atrial Fibrillation: Emergense of Alternative Oral Anticoagulants” by Katsnelson, et al (Stroke. 2012;43:1179–1185), the following corrections are needed:
The authors used intent to treat analysis for rivaroxaban to keep the uniformity with other studies reported.
In the Figure, the labels of the first 2 columns in the graph were reversed. Dabi 110 mg should be on the left of Dabi 150 mg. The corrected figure is below.
These corrections have been made to the online version of the article.
- © 2012 American Heart Association, Inc.